
    
      The Phase 1 will consist of a dose escalation of ALX148 in combination with azacitidine to
      evaluate safety and tolerability, and to identify the recommended Phase 2 dose of ALX148 in
      combination with azacitidine. The Phase 2 will evaluate the efficacy of ALX148 in combination
      with azacitidine compared to azacitidine alone for patients with previously untreated higher
      risk MDS.
    
  